Otis Brawley: CMS Got it Right in Lung Cancer Screening Coverage Decision

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This week the Centers for Medicare & Medicaid Services issued a proposed rule stating that the scientific evidence was sufficient to support reimbursement for counseling on the risks and benefits of lung cancer screening as well as lung cancer screening with low dose computed tomography in high risk individuals and once per year. CMS will pay for such services when provided to beneficiaries at high risk for lung cancer and when provided by physicians and centers with specific qualifications.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Otis W. Brawley, MD, MACP
Chief scientific and medical officer, American Cancer Society
Table of Contents

YOU MAY BE INTERESTED IN

In 1971, the National Cancer Act set the United States on a path to confront one of its most formidable public health challenges. More than five decades later, the progress is undeniable. The latest 2026 report from the American Cancer Society shows continued declines in overall cancer mortality and improvements in survival for many major cancer types. Recent advances in early detection, prevention, and treatment are saving lives.
Otis W. Brawley, MD, MACP
Chief scientific and medical officer, American Cancer Society

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login